Novel AR-Directed Agents Transform Nonmetastatic CRPC Paradigm
Elisabeth I. Heath, MD, FACP, discusses 3 pivotal trials and how they have impacted clinical practice in nonmetastatic castration-resistant prostate cancer.
Related Articles
Dr Powles on Implications of the CREST Study of Sasanlimab Plus BCG in BCG-Naive NMIBC
Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.
FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies
SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.
Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mutational Status
Mazyar Shadman, MD, MPH, discusses key efficacy and safety findings from arm D of the SEQUOIA trial of first-line zanubrutinib plus venetoclax in CLL/SLL.
Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC
Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.
Ibrutinib Plus Venetoclax and A CD20 Monoclonal Antibody Increases MRD Negativity in Untreated MCL
Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.
FDA Grants Orphan Drug Designation to CID-078 for SCLC
The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.
QOL Data Could Help Support Switch to Camizestrant in HR+ Breast Cancer After Emergence of ESR1 Mutation
Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.
ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma
Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.